KUR-101 is under clinical development by Atai Life Sciences and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KUR-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KUR-101 (deuterated mitragynine) is under investigation for the treatment of pain and opioid use disorder. The drug candidate is a synthetic derivative of alkaloid derived from Mitragyna speciosa plant (kratom) and acts by targeting human mu opioid receptors and human Kappa opioid receptors. It is administered through oral route.
Atai Life Sciences overview
Atai Life Sciences (ALS) is a biotechnology company that develops innovative treatments for addressing depression, anxiety, addiction, other unmet medical needs and mental health disorders. It aims to accelerate the development of new medicines across all its companies to receive clinically meaningful, and sustained behavioral change in mental health of patients. The company has its offices in New York, London and Berlin. ALS is headquartered in Berlin, Germany.
For a complete picture of KUR-101’s drug-specific PTSR and LoA scores, buy the report here.